The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
The state’s industry draws inspiration from medicine as well as agriculture.
Science-based tinnitus therapeutics are finally coming into their own.
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?
Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.
Researchers use molecular keys, chisels, and crowbars to open the last great biochemical barricade in the body—the blood-brain barrier.
Companies are bursting at the seams with tools to engineer pharma’s next magic bullet: the new and improved antibody.
After implantation, the tissue developed blood vessels and became integrated into neuronal networks in the animals’ brains.
The nationwide experiment will initially include around 100,000 volunteers.
The 20-year project calls into question the conventional wisdom about the role plants will play in mitigating future climate change.
The US Senate narrowly approved the politician, who does not have a science background.
© 1986-2018 The Scientist
